Go to Hepatitis B Foundation home page

Emmet Keeffe, MD: "Evolving Treatment Strategies for Chronic Hepatitis B"

Emmet Keeffe, M.D., the featured Keynote Speaker at the 4th Annual B Informed Patient Conference (June 2004), presents "Evolving Treatment Strategies for Chronic Hepatitis B" offering useful treatment information for both patients and healthcare providers.

The annual B Informed Patient Conference, sponsored by the Hepatitis B Foundation and the Hepatitis B Information and Support List, draws attendees from around the world and is the only conference geared specifically toward hepatitis B patients and families.

Dr. Keeffe is the Chief of Hepatology and Co-Director of the Liver Transplant Program of Stanford University, Stanford California as well as the President of the American Gastroenterological Association.

Dr. Keeffe has been very active in national organizations in his field and has held several leadership positions. He holds several editorial positions as well as several internet gastroenterology and hepatology editorial boards.

To start at the beginning of the presentation, simply click on one of the answer links (video, audio, or text-only) to the right of the first question, and follow the arrows in each successive page, to move to the next question. Alternatively, you can click on the answer to a specific question, and/or use the Questions link at the top of a Q&A page, to return to this list.

Questions Answer Formats
1. Introduction to Evolving Treatment Strategies for Chronic Hepatitis B
2. What is the prevalence rate of chronic hepatitis B in the world?
3. How many people have chronic hepatitis B?
4. What is the natural history and progression of hepatitis B?
5. What is the natural clearance rate of the surface and e-antigen?
6. What is the risk of liver cancer for someone with active chronic hepatitis B?
7. Is the presence of hepatitis B DNA associated with increased risk of liver cancer?
8. Is there more than one type of hepatitis B virus?
9. What is e-antigen negative chronic hepatitis B?
10. Are there different genotypes of the hepatitis B virus?
11. What are the demographics of hepatitis B genotypes in the US?
12. Is the response to therapy related to HBV genotypes?
13. What are the phases of chronic hepatitis B?
14. How do doctors assess chronic hepatitis B?
15. What are the serological markers for hepatitis B?
16. What are the AASLD Practice Guidelines for treatment of chronic hepatitis B?
17. Are there other counseling recommendations for someone with chronic hepatitis B?
18. Should someone with chronic hepatitis B be screened for liver cancer?
19. What are the licensed treatments for chronic hepatitis B in the US?
20. What are the response, duration and durability for the three hepatitis B treatments?
21. Are there other notable differences between the treatments, including side-effects?
22. Does the hepatitis B virus develop resistance to the anti-viral treatments?
23. Are the oral treatments for hepatitis B complimentary in treating resistance? (lamivudine resistance and adefovir)
24. Are the oral treatments for hepatitis B complimentary in treating resistance? (adefovir resistance and lamivudine)
25. Is pegylated interferon effective in treating chronic hepatitis B?
26. What is the combined response of treatment between interferon and pegylated interferon?
27. How has the HBV treatment landscape changed?
28. Who participated in writing the HBV Treatment Algorithm?
29. Why was the HBV Treatment Algorithm written?
30. What are the key issues with the current guidelines focused on by the Treatment Algorithm?
31. What are the AASLD Treatment Guidelines for hepatitis B?
32. What are the recommendations made by the treatment Algorithm panel?
33. What is the appropriate DNA level for initiating treatment of chronic hepatitis B?
34. What is the treatment algorithm for patients with HBeAg positive compensated disease?
35. What is the treatment algorithm for patients with HBeAg negative compensated disease?
36. What is the treatment algorithm for patients with compensated cirrhosis?
37. What is the treatment algorithm for patients with decompensated cirrhosis?
38. What are the advantages and disadvantages of the current approved hepatitis B treatments?
39. Are there new treatments on the horizon for treatment of chronic hepatitis B?